1. Volume 135, Issue 5, Pages 1493-1499 (November 2008)
Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study 
Brian G. Feagan, Remo Panaccione, William J. Sandborn, Geert R. D'Haens, Stefan Schreiber, Paul J. Rutgeerts, Edward V. Loftus, Kathleen G. Lomax, Andrew P. Yu, Eric Q. Wu, Jingdong Chao, Parvez Mulani 
Gastroenterology 
Volume 135, Issue 5, Pages (November 2008)
DOI: /j.gastro
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1
Kaplan–Meier analysis of risk of all-cause hospitalization in different treatment groups in the CHARM trial. Kaplan–Meier method was used to estimate hospitalization risk. Randomization (week 4) was used as a starting date. Log-rank test for equality over strata demonstrated that hospitalization risk of patients on placebo regimen was significantly different than the hospitalization risk of patients on adalimumab every other week (P < .01), adalimumab weekly (P < .01) and patients in the combined adalimumab group (P < .01).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

3. Figure 2
Kaplan–Meier analysis of risk of Crohn's disease–related hospitalization in different treatment groups in the CHARM trial. Kaplan–Meier method was used to estimate hospitalization risk. Randomization (week 4) was used as a starting date. Log-rank test for equality over strata showed that hospitalization risk of patients on placebo regimen was significantly different from the hospitalization risk of patients on adalimumab every other week (P = .02), adalimumab weekly (P < .001), and patients in the combined adalimumab group (P = .01).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions